<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5035">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02128802</url>
  </required_header>
  <id_info>
    <org_study_id>130912</org_study_id>
    <nct_id>NCT02128802</nct_id>
  </id_info>
  <brief_title>Obesity Surgery and Kidney Transplant for Patients With Obesity and Renal Failure</brief_title>
  <official_title>Weight Reduction Surgery Followed by Kidney Transplantation for Patients With Class III Obesity and Renal Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastric Bypass followed by renal transplantation is superior to medical management followed
      by renal transplant for patients with severe obesity and renal failure.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Ability to reach medical suitability for renal transplant within 18 months after initiating treatment and the change and trajectory of health-related quality of life (HRQOL)</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Outcomes will be measured based on weight loss and a variety of validated surveys and questionnaires to measure HRQOL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of patients who die from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight loss</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Amount of weight lost at various points over the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical outcomes</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of surgical complications including but not limited to leak rate, stricture rate, pulmonary embolism, and infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development or regression of diabetes</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Including but not limited to start of stop of insulin therapy, amount of insulin required, and start or stop of or cal medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development or regression of other comorbidities</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Development or regression of other diseases including but not limited to hypertension, coronary artery disease, and skin infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care utilization</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>This outcome measure includes but is not limited to the amount of money spent on health care, total hospitalization, days of hospitalization, and procedures required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>This outcome includes but is not limited to measures of albumin, pre-albumin, and caloric intake.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormonal and metabolic status</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>This outcome includes but is not limited to measurement of protein catabolism, creatinine clearance, and serum prealbumin.  In addition, protein and iron metabolism will be measured using serum albumin, transferrin and ferritin.  Glucose metabolism will be measured by glucose and insulin levels.  regression of the disease.  Lipid metabolism will be assessed with triglyceride levels, very-low density lipoproteins, and cholesterol.  Micronutrient levels will be measured with vitamin D, thiamin, B12, and folate.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Prograf dosing</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>This outcome will assess the amount of prograf required for therapeutic levels</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Severe Obesity</condition>
  <condition>Renal Failure</condition>
  <arm_group>
    <arm_group_label>Surgical Gastric Bypass</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo surgical gastric bypass according to standard institutional protocols</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical Weight Loss Management</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive best practices medical management for weight loss under current institutional protocols</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Gastric Bypass</intervention_name>
    <arm_group_label>Surgical Gastric Bypass</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Weight Loss Program</intervention_name>
    <arm_group_label>Medical Weight Loss Management</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index 40-55 kg/m2

          -  Age less than 55 years

          -  Available support person

          -  Adequate insurance

          -  All other criteria required for renal transplantation

        Exclusion Criteria:

          -  Schizophrenia

          -  Bipolar disorder

          -  Crohn's disease

          -  Human Immunodeficiency Virus

          -  Cirrhosis

          -  Prior weight loss surgery

          -  Prior mesh hernia repair

          -  Prior anti-reflux surgery

          -  Inability to walk 200 feet

          -  Significant coronary disease

          -  Significant lung disease - Fixed expiratory volume 1 less than 75% or on oxygen

          -  Addiction to alcohol or drugs

          -  Inability to quit smoking

          -  Jehovah's witness

          -  Non-compliance with dialysis regimen

          -  Previous renal transplant

          -  Non-English speaking
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Seth Karp, MD</last_name>
    <phone>6159368989</phone>
    <email>seth.karp@vanderbilt.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Seth Karp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 29, 2014</lastchanged_date>
  <firstreceived_date>April 23, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Seth Karp</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Renal failure</keyword>
  <keyword>Gastric bypass</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
